351例各类肝病患者血清抗—HCV的调查

应用固相酶联免疫洲定方法(ELISA),检测351例不同类型肝病患者血清丙型肝炎病毒抗体(抗-HCV)。输血后非甲非乙型肝炎(NANBH)、散发性NANBH和非乙型肝硬化抗-HCV阳性率分别为86%、34.9%和76.2%;28例急性甲肝均阴性;乙肝患者为23.3%;原发性肝癌为16.0%。有输血史乙肝患者抗-HCV阳性率高于无输血史者。提示除甲肝外,各类肝病患者均为HCV高危人群。输血液制品是乙肝合并丙肝的主要原因。

Investigation for Anti-HCV in Serum Samples of 351 Patients with Varieties of Liver Diseases

The serum samples from 351 patients with varieties of liver diseases were detected for anti-HCV by ELISA. Of the patients with post-transfusion NANBH, 86% (74/86) were anti-HCV positive; of the patients with sporadic NANBH, 34.9% (22/63)positive; of the patients with non-B cirrhosis, 76.2% (16/21) positive; of the patients with hepatits B, 23.3% (24/103) positive;of the patients with primary hepatocellular carcinoma, 16.0% (8/50) positive; none of 28 patients with hepatitis A were anti-HCV positive. of the patients with hepatitis B, anti-HCV positive rate was higher in the patients who had a history of blood transfusion than in those who had no such history. The results suggested that (a) the patients with liver diseases apart from hepatitis A are HCV high risk population and HCV infection can not be ignored in those liver disease patients; (b) blood transfusion is the main cause of HBV-HCV double infection.